Blueprint Medicines (BPMC) Gets a Hold from Barclays
In a report released today, Peter Lawson from Barclays maintained a Hold rating on Blueprint Medicines (BPMC – Research Report), with a price ...
'Burner photos' –why rubbish shots are an integral part of the creative process
This film photographer's concept of 'burner photos' is genius! Here's why bad photos will help you to grow as a ...
One of the World’s Largest Architecture Firms Offers a Blueprint for Successful Co-Leadership
Elizabeth Brink and Jordan Goldstein of Gensler explain how they work as co-CEOs, and how shared leadership helps make the firm move faster.
2 Soaring Stocks to Hold for the Next 20 Years
If the player has a track record of earnings growth and bright future prospects, you actually may miss out if you sell today ...
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by StockNews.com
StockNews.com lowered shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a hold rating to a sell rating in a ...
Zacks.com on MSN5d
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.82 per share a year ago. These figures ...